相关实验视频

Updated: Jan 12, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

开发针对上皮膜蛋白2-高表达肺癌的抗体药物合物

Mengge Zheng¹, Su Hang², Changyong Hu³

¹Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Cell death & disease

|November 1, 2025

概括

研究人员确定了一种新的抗体,FK002,向表皮膜蛋白2 (EMP2) 用于抗体-药物合物 (ADC) 治疗. 这种EMP2导向的ADC,FK002-exatecan,在临床前模型中显示出消除肺癌细胞的前景.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

肺癌的治疗仍然具有挑战性.
抗体-药物合物 (ADC) 是一个有前途的向治疗方法.
确定新的点对于有效治疗肺癌至关重要.

研究的目的:

为了识别一种针对肺癌细胞的新型抗体.
开发和评估一种针对上皮膜蛋白2 (EMP2) 的抗体-药物联合体 (ADC).
在临床前肺癌模型中验证EMP2定向ADC的有效性.

主要方法:

基于组织微阵列的抗体库查以识别FK002抗体.
开发FK002-exatecan,一个针对EMP2和exatecan有效载荷的ADC.
在体外和体内实验中使用肺癌细胞系,异种移植小鼠模型,患者衍生异种移植 (PDX) 和患者衍生瘤样细胞群 (PTC) 的实验.

主要成果:

FK002抗体在瘤细胞膜上特别与EMP2结合.
FK002-exatecan在各种肺癌模型中表现出强大和特定的抗瘤活性.
该机制涉及EMP2结合,内化,催产素释放,细胞循环停止和细胞亡.

结论:

表皮膜蛋白2 (EMP2) 是用于肺癌治疗的新型分子标.
导向EMP2的ADC,FK002-exatecan,是肺癌的潜在治疗剂.
这项研究为开发针对性ADC用于肺癌治疗提供了基础.

更多相关视频

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...